


## Supplemental Data

### Coding Variants at Hexa-allelic Amino Acid 13 of HLA-DRB1 Explain Independent SNP


#### Associations with Follicular Lymphoma Risk

Jia Nee Foo, Karin E. Smedby, Nicholas K. Akers, Mattias Berglund, Ishak D. Irwan, Xiaoming Jia, Yi Li, Lucia Conde, Hatef Darabi, Paige M. Bracci, Mads Melbye, Hans-Olov Adami, Bengt Glimelius, Chiea Chuen Khor, Henrik Hjalgrim, Leonid Padyukov, Keith Humphreys, Gunilla Enblad, Christine F. Skibola, Paul I.W. de Bakker, and Jianjun Liu




**Figure S1. Region Association Plot before and after Conditioning on Alleles at Position 13**

Regional association plot of bi-allelic logistic regression test P-values done on imputed amino acid alleles and SNPs surrounding rs2647012 and rs10484561 before (black) and after (red) conditioning on alleles at position 13 in SCALE GWAS samples




**Figure S2. Six Possible Encoded Amino Acids at Position 13 in the HLA-DR Binding Groove**

Amino acid 13 (yellow) in the binding groove of structure (PDB ID: 1AQD) of HLA-DR1 (DRA, DRB1 0101, Phe at position 13) protein (extracellular domain) complexed with endogenous peptide (red). Other amino acid alleles were mutated *in silico* using the DeepView/Swiss-PdbViewer program (<http://spdbv.vital-it.ch/>).



**Figure S3. Genotyping of Amino Acid 13 Based on Sequence Chromatograms**

All 21 genotypes (the two residues present in each individual, each coded as Y=Tyr, F=Phe, G=Gly, S=Ser, R=Arg, H=His) could be called and distinguished by visual inspection of the chromatograms.



**Figure S4. Flowchart on Study Design and Data Acquisition**

Flowchart on the imputation, association testing (showing filters for SNPs imputed by IMPUTEv2) and selection of variants for validation in additional samples. The datasets (and sample sizes) used as reference panels for imputation are shown in red boxes and the discovery or replication datasets used for association testing are shown in blue boxes.

**Table S1. Conditional Analysis on FL-Associated SNPs in the HLA Class II Region**

SNP	Position			P	OR condition	P condition	$r^2 / D'$	$r^2 / D'$	$r^2 / D'$
	(b37)	A1	OR (95% CI)		rs2647012 + rs10484561	rs2647012 + rs10484561			
	chr6								
rs4530903	32581889	T	1.545 (1.183-2.018)	0.00139	0.509 (0.186-1.392)	0.188	0.085/0.979	0.92/0.991	0.154/0.989
rs9268853	32429643	C	1.302 (1.087-1.559)	0.00409	1.311 (0.995-1.727)	0.054	0.324/0.991	0.07/0.962	0.577/1
rs2621416	32741868	C	1.419 (1.163-1.732)	0.00058	1.056 (0.840-1.328)	0.642	0.207/0.843	0.147/0.641	0.187/0.611
rs2647046	32668336	A	0.617(0.510-0.747)	6.84E-07	NA	NA	0.991/0.996	0.09/0.934	0.558/0.986
rs9276490	32718681	A	0.695 (0.576-0.840)	0.000161	0.871 (0.703-1.080)	0.208	0.263/0.603	0.077/0.735	0.082/0.322
rs7453920	32730012	A	0.689 (0.570-0.833)	0.000116	0.854 (0.687-1.060)	0.152	0.27/0.605	0.075/0.738	0.079/0.319

Linkage disequilibrium and conditional analyses on rs2647012, rs10484561 and rs9378212 and the HLA SNPs reported in a recent FL GWAS by Vijai et al.<sup>4</sup> that were either genotyped (only rs7453920) or imputed in the SCALE discovery GWAS dataset.

**Table S2. Association Results at Amino Acids 11 and 13 in the Discovery and Replication Data Sets**

	Discovery GWAS (379 cases/791 controls)			Replication 1 (222 cases/220 controls)			Replication 2 (88 cases/1,435 controls)			Meta-analysis		
	Freq Cases/ Controls	OR (95% CI)	P	Freq Cases/ Controls	OR (95% CI)	P	Freq Cases/ Controls	OR (95% CI)	P	OR	P <sub>het</sub>	I <sup>2</sup>
Asp11	0.022/ 0.017	1.311 (0.716-2.402)	0.380	0.009/ 0.016	0.558 (0.161-1.935)	0.358	0.040/ 0.021	1.928 (0.871-4.270)	0.105	1.326	0.218	26.3
Gly11	0.128/ 0.097	1.358 (1.039-1.773)	0.025	0.162/ 0.121	1.388 (0.955-2.017)	0.085	0.091/ 0.077	1.180 (0.705-1.974)	0.528	1.338	4.36x10 <sup>-3</sup>	0
Leu11	0.168/ 0.106	1.724 (1.338-2.222)	2.59x10 <sup>-5</sup>	0.182/ 0.093	2.211 (1.465-3.337)	1.58 x 10 <sup>-4</sup>	0.227/ 0.115	2.149 (1.498-3.082)	3.22x10 <sup>-5</sup>	1.922	4.82x10 <sup>-12</sup>	0
Pro11	0.124/ 0.151	0.803 (0.624-1.032)	0.087	0.124/ 0.198	0.568 (0.391-0.826)	3.03 x 10 <sup>-3</sup>	0.114/ 0.165	0.654 (0.408-1.050)	0.079	0.710	4.26x10 <sup>-4</sup>	16.4
Ser11	0.330/ 0.426	0.666 (0.555-0.799)	1.17x10 <sup>-5</sup>	0.360/ 0.421	0.775 (0.590-1.018)	0.067	0.358/ 0.411	0.805 (0.588-1.100)	0.173	0.717	1.67x10 <sup>-6</sup>	0
Val11	0.228/ 0.204	1.150 (0.937-1.411)	0.181	0.158/ 0.152	1.042 (0.723-1.504)	0.824	0.165/ 0.211	0.740 (0.493-1.112)	0.147	1.050	0.558	44.3
Ser13	0.255/ 0.358	0.615 (0.506-0.747)	9.30x10 <sup>-7</sup>	0.315/ 0.375	0.763 (0.576-1.012)	0.061	0.290/ 0.350	0.761 (0.546-1.062)	0.108	0.677	1.18x10 <sup>-7</sup>	5.9
Arg13	0.124/ 0.151	0.803 (0.624-1.032)	0.087	0.124/ 0.198	0.568 (0.391-0.826)	3.03 x 10 <sup>-3</sup>	0.114/ 0.165	0.654 (0.408-1.050)	0.079	0.710	4.26x10 <sup>-4</sup>	16.4
Gly13	0.075/ 0.068	1.111 (0.795-1.553)	0.538	0.045/ 0.045	0.991 (0.526-1.865)	0.977	0.057/ 0.057	1.000 (0.521-1.922)	0.999	1.069	0.629	0
His13	0.220/ 0.195	1.161 (0.943-1.428)	0.159	0.146/ 0.143	1.026 (0.705-1.494)	0.892	0.165/ 0.203	0.774 (0.513-1.166)	0.221	1.060	0.489	34.0
Tyr13	0.128/ 0.097	1.358 (1.039-1.773)	0.025	0.162/ 0.121	1.388 (0.955-2.017)	0.085	0.091/ 0.077	1.180 (0.705-1.974)	0.528	1.338	4.36x10 <sup>-3</sup>	0
Phe13	0.198/ 0.132	1.649 (1.303-2.087)	3.09x10 <sup>-5</sup>	0.203/ 0.118	1.881 (1.296-2.731)	8.90 x 10 <sup>-4</sup>	0.284/ 0.148	2.160 (1.547-3.016)	6.11x10 <sup>-6</sup>	1.820	6.71x10 <sup>-12</sup>	0

P<sub>het</sub>: Cochrane's Q test P-value; I<sup>2</sup>: inconsistency

**Table S3. Association Statistics at rs2647012, rs10484561, and rs9268839/rs9378212 before and after Adjustment for Alleles at Amino Acid Position 13**

Sample collection Cases/Controls		Before adjustment		After adjustment	
<b>rs2647012</b>		<b>OR (95% CI)</b>	<b>P</b>	<b>OR (95% CI)</b>	<b>P</b>
<b>Discovery</b> 379 / 791		0.603 (0.500-0.727)	1.10x10 <sup>-7</sup>	0.851 (0.582-1.244)	0.405
<b>Replication 1</b> 222 / 220		0.551 (0.418-0.726)	2.33x10 <sup>-5</sup>	0.636 (0.432-0.936)	0.0216
<b>Replication 2</b> 88 /1435		0.831 (0.609-1.135)	0.245	1.771 (0.965-3.250)	0.065
<b>Meta-analysis</b>		<b>P</b>	<b>OR</b>	<b>P<sub>het</sub></b>	<b>I<sup>2</sup></b>
<b>Fixed effects</b>		4.72x10 <sup>-11</sup>	0.628	0.125	51.99
<b>Random effects</b>		3.33x10 <sup>-5</sup>	0.639		
<b>rs10484561</b>		<b>OR (95% CI)</b>	<b>P</b>	<b>OR (95% CI)</b>	<b>P</b>
<b>Discovery</b> 379 / 791		1.686 (1.324-2.148)	2.33x10 <sup>-5</sup>	1.558 (0.864-2.808)	0.140
<b>Replication 1</b> 222 / 220		2.570 (1.701-3.883)	7.41x10 <sup>-6</sup>	6.006 (2.226-16.2)	4.00x10 <sup>-4</sup>
<b>Replication 2</b> 88 /1435		1.791 (1.237-2.595)	2.05 x 10 <sup>-3</sup>	0.614 (0.311-1.212)	0.160
<b>Meta-analysis</b>		<b>P</b>	<b>OR</b>	<b>P<sub>het</sub></b>	<b>I<sup>2</sup></b>
<b>Fixed effects</b>		2.61x10 <sup>-11</sup>	1.857	0.220	33.97
<b>Random effects</b>		9.14x10 <sup>-8</sup>	1.900		
<b>rs9268839/rs9378212</b>		<b>OR (95% CI)</b>	<b>P</b>	<b>OR (95% CI)</b>	<b>P</b>
<b>Discovery</b> 379 / 791		1.637 (1.372-1.953)	4.57x10 <sup>-8</sup>	NA	NA

Given the high heterogeneity observed across the three datasets, both the fixed effects and random effects models were considered in the meta-analysis. P<sub>het</sub>: Cochrane's Q test P-value; I<sup>2</sup>: inconsistency.

**Table S4. Haplotype Analysis of rs10484561 and rs2647012 with the Six Amino Acid Residues at Position 13 in a Meta-analysis across All Three Data Sets**

Phased haplotype: AA13 – rs2647012 – rs10484561	Discovery		Replication 1		Replication 2		Meta-analysis		
	MAF Cases/ Controls	OR (95% CI) P	MAF Cases/ Controls	OR (95% CI) P	MAF Cases/ Controls	OR (95% CI) P	OR (95% CI)	P	P <sub>het</sub> / I <sup>2</sup>
Tyr – C – A	0.128/ 0.097	1.36 (1.04-1.77) 0.025	0.151/ 0.121	1.28 (0.88-1.87) 0.200	0.090/ 0.076	1.19 (0.71-1.99) 0.510	1.31 (1.07-1.60)	8.58E-03	0.896/ 0
Phe – C – A	0.024/ 0.018	1.34 (0.74-2.42) 0.332	0.011/ 0.021	0.54 (0.18-1.64) 0.277	0.056/ 0.018	3.37 (1.65-6.87) 8.58E-04	1.62 (1.06-2.47)	0.025	0.017/ 75.6
Phe – C – C	0.174/ 0.113	1.66 (1.30-2.12) 5.86E-05	0.189/ 0.091	2.396 (1.58-3.63) 3.64E-05	0.208/ 0.127	1.77 (1.22-2.57) 2.64E-03	1.81 (1.51-2.18)	2.55E-10	0.322/ 11.7
Gly – C – A	0.074/ 0.068	1.09 (0.78-1.53) 0.617	0.045/ 0.046	0.99 (0.53-1.87) 0.977	0.056/ 0.055	1.02 (0.53-1.96) 0.965	1.06 (0.81-1.39)	0.682	0.957/ 0
His – C – A	0.220/ 0.193	1.17 (0.95-1.44) 0.139	0.146/ 0.143	1.03 (0.71-1.49) 0.892	0.152/ 0.201	0.71 (0.46-1.08) 0.108	1.05 (0.89-1.25)	0.538	0.111/ 54.6
Arg – C – A	0.008/ 0.007	1.13 (0.44-2.90) 0.808	0.025/ 0.023	1.10 (0.46-2.63) 0.840	0.023/ 0.012	1.79 (0.67-4.80) 0.245	1.28 (0.75-2.19)	0.368	0.725/ 0
Arg – T – A	0.115/ 0.144	0.78 (0.60-1.01) 0.061	0.099/ 0.173	0.52 (0.35-0.78) 0.002	0.090/ 0.153	0.55 (0.33-0.93) 0.025	0.67 (0.55-0.82)	9.80E-05	0.193/ 39.1
Ser – C – A	0.050/ 0.068	0.72 (0.49-1.06) 0.098	0.119/ 0.111	1.08 (0.72-1.60) 0.722	0.028/ 0.077	0.35 (0.14-0.86) 0.022	0.81 (0.62-1.05)	0.117	0.059/ 64.7
Ser – T – A	0.201/ 0.290	0.62 (0.50-0.76) 6.62E-06	0.194/ 0.264	0.69 (0.51-0.94) 0.018	0.253/ 0.266	0.94 (0.66-1.32) 0.706	0.69 (0.59-0.81)	2.69E-06	0.132/ 50.6

P<sub>het</sub>: Cochrane's Q test P-value; I<sup>2</sup>: inconsistency

**Table S5. Haplotype Analysis of Alleles at Amino Acids 11 and 13 in the Meta-analysis across All Three Data Sets**

Haplotype	Average Frequency in controls	P	OR (95% CI)	P <sub>het</sub>	I <sup>2</sup>	LD ( $r^2$ ) in SCALE
<b>Leu11-Phe13</b>	0.105	4.82x10 <sup>-12</sup>	1.922 (1.597-2.313)	0.468	0	0.79
<b>Asp11-Phe13</b>	0.018	0.218	1.326 (0.847-2.078)	0.257	26.3	0.095
<b>Gly11-Tyr13</b>	0.098	0.004	1.338 (1.095-1.634)	0.870	0	1
<b>Val11-His13</b>	0.180	0.489	1.060 (0.898-1.252)	0.220	34.0	0.95
<b>Ser11-Gly13</b>	0.057	0.629	1.069 (0.816-1.400)	0.929	0	0.12
<b>Pro11-Arg13</b>	0.171	4.26x10 <sup>-4</sup>	0.710 (0.586-0.859)	0.302	16.4	1
<b>Ser11-Ser13</b>	0.361	1.18x10 <sup>-7</sup>	0.677 (0.586-0.782)	0.345	5.9	0.74

P<sub>het</sub>: Cochrane's Q test P-value; I<sup>2</sup>: inconsistency; LD: linkage disequilibrium between the encoded residues at positions 11 and 13.

**Table S6. Amino Acid Residue Found at Positions 11 and 13 of Each Classical *HLA-DRB1* Allele**

HLA type	11	13
DRB1*01:01	Leu	Phe
DRB1*01:02	Leu	Phe
DRB1*01:03	Leu	Phe
DRB1*01:04	Leu	Phe
DRB1*03:01	Ser	Ser
DRB1*04:01	Val	His
DRB1*04:02	Val	His
DRB1*04:03	Val	His
DRB1*04:04	Val	His
DRB1*04:05	Val	His
DRB1*04:06	Val	His
DRB1*04:07	Val	His
DRB1*04:08	Val	His
DRB1*07	Gly	Tyr
DRB1*08	Ser	Gly
DRB1*09	Asp	Phe
DRB1*10:01	Val	Phe
DRB1*11:01	Ser	Ser
DRB1*11:02	Ser	Ser
DRB1*11:03	Ser	Ser
DRB1*11:04	Ser	Ser
DRB1*12:01	Ser	Gly
DRB1*13:01	Ser	Ser
DRB1*13:02	Ser	Ser
DRB1*13:03	Ser	Ser
DRB1*13:04	Ser	Ser
DRB1*14:01	Ser	Ser
DRB1*14:02	Ser	Ser
DRB1*14:03	Ser	Ser
DRB1*14:04	Ser	Gly
DRB1*15:01	Pro	Arg
DRB1*16:01	Pro	Arg

Data from the EMBL-EBI Immunogenetics HLA Database (<http://www.ebi.ac.uk/imgt/hla/>)